- Home
- LIXT vs XXII Comparison
LIXT vs XXII Comparison
Compare LIXT & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- XXII
- Stock Information
- Founded
- LIXT 2005
- XXII 1998
- Country
- LIXT United States
- XXII United States
- Employees
- LIXT N/A
- XXII N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- XXII Medicinal Chemicals and Botanical Products
- Sector
- LIXT Health Care
- XXII Health Care
- Exchange
- LIXT Nasdaq
- XXII Nasdaq
- Market Cap
- LIXT 4.1M
- XXII 3.9M
- IPO Year
- LIXT N/A
- XXII N/A
- Fundamental
- Price
- LIXT $1.93
- XXII $5.50
- Analyst Decision
- LIXT
- XXII
- Analyst Count
- LIXT 0
- XXII 0
- Target Price
- LIXT N/A
- XXII N/A
- AVG Volume (30 Days)
- LIXT 33.2K
- XXII 105.4K
- Earning Date
- LIXT 11-12-2024
- XXII 11-12-2024
- Dividend Yield
- LIXT N/A
- XXII N/A
- EPS Growth
- LIXT N/A
- XXII N/A
- EPS
- LIXT N/A
- XXII N/A
- Revenue
- LIXT N/A
- XXII $17,304,000.00
- Revenue This Year
- LIXT N/A
- XXII $56.94
- Revenue Next Year
- LIXT N/A
- XXII $2.98
- P/E Ratio
- LIXT N/A
- XXII N/A
- Revenue Growth
- LIXT N/A
- XXII N/A
- 52 Week Low
- LIXT $1.31
- XXII $3.90
- 52 Week High
- LIXT $4.40
- XXII $581.85
- Technical
- Relative Strength Index (RSI)
- LIXT 57.92
- XXII 18.51
- Support Level
- LIXT $1.85
- XXII $3.90
- Resistance Level
- LIXT $2.65
- XXII $12.29
- Average True Range (ATR)
- LIXT 0.18
- XXII 1.06
- MACD
- LIXT 0.03
- XXII -0.59
- Stochastic Oscillator
- LIXT 43.37
- XXII 4.36
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.